Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NouvNeu001 in Multiple System Atrophy
NCT07289477Phase 1Recruiting
- Sponsor
- iRegene Therapeutics
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NOUVNEU001 in multiple system atrophy (MSA) (2 arms), sponsored by iRegene Therapeutics. Primary endpoint: Incidence and severity of Adverse Events as Assessed by CTCAE V5.0 at 52 weeks. Started Jan 2026; status: recruiting.
02
Drugs
NOUVNEU001
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT07289477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289477.